Mirae Asset Global Investments Co., Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $54.3 Billion
- Q1 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 13,906 shares of PHAT stock, worth $143,231. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,906
Previous 13,636
1.98%
Holding current value
$143,231
Previous $124,000
18.55%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.9 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$36 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.3 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $404M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...